Digital Therapeutics & Medical Devices for Migraine Market Size is predicted to witness a 8.6% CAGR during the forecast period for 2024-2031.
Digital therapeutics and medical devices for migraines describe interventions that use technology to alleviate and control migraine symptoms. Mindfulness exercises and cognitive behavioral therapy for migraine symptom management are common in digital treatments. Several factors contribute to the market growth in the coming years, such as developments in digital health technology, heightened migraine awareness and prevalence, and a rising desire for alternatives to pharmaceutical treatments. Further factors fueling market growth include the increasing availability of telemedicine services and the development of AI and ML-powered tailored healthcare solutions. In addition, digital therapeutics and medical devices for migraines are seeing increased use as digital health solutions become more acceptable and are used by patients and healthcare providers worldwide, driving market expansion.
However, digital therapeutics & medical devices for migraine market slow down the market growth due to various factors such as their high cost, challenges with regulations, expensive development and implementation, and worries over data safety and confidentiality. Moreover, the market is expected to experience growth throughout the forecast time period due to technological advancements, strong alliances with government agencies, a younger population, and an increase in healthcare expenditure.
Competitive Landscape
Some Major Key Players In The Digital Therapeutics & Medical Devices for Migraine Market:
- Relivion MG
- gammaCore
- WeatherX
- Aculief
- Theragun
- Allay Lamp
- Shakti Mat
- Allodynic Therapeutics, LLC
- Amgen Inc.
- Bayer AG
- Cefaly Technology
- Cirrus Healthcare Products
- electroCore, Inc
- Eli Lilly and Company
- eNeura Inc.
- GlaxoSmithKline plc.
- Neurolief Ltd.
- Neuros Medical, Inc.
- Novartis AG
- Pfizer Inc.
- Salvia BioElectronics B.V.
- Theranica Bio-Electronics Ltd.
- Other Prominent Players
Market Segmentation:
The digital therapeutics & medical devices for migraine market is segmented based on type, age group, and mode of action. Based on type, the market is segmented into arm devices, neck devices, head/forehead devices, and others. By age group, the market is segmented into those above 18 years and those above 12 years. By mode of action, the market is segmented into electrical pulse, mild electrical stimulation, and deep muscle treatment.
Based On Type, The Head/Forehead Device Segment Is Accounted As A Major Contributor In The Digital Therapeutics & Medical Devices For Migraine Market.
The head/forehead device category will hold a major share of the global digital therapeutics & medical devices for migraine market in 2023. This is because of the straightforward way they relieve migraine symptoms. These gadgets offer a non-invasive and drug-free solution by utilizing monitoring techniques. They are becoming popular as an alternative to standard pharmaceutical therapies due to their efficacy and user-friendliness, driving market expansion.
The Above 18 Years Segment Witnessed Growth At A Rapid Rate.
The above 18 years segment is projected to grow rapidly in the global digital therapeutics & medical devices for migraine market because migraines frequently strike adults. Due to the desire to avoid drug usage and keep productivity high, more and more adults are looking for effective non-pharmacological ways to control migraines. This is especially true among working-age adults. The increasing knowledge and willingness of this demographic to embrace digital health solutions also contribute to the segment’s growth in the future.
In The Region, The North American Digital Therapeutics & Medical Devices For Migraine Market Holds A Significant Revenue Share.
The North American digital therapeutics & medical devices for migraine market is expected to record the maximum market share in revenue in the near future. The region is propelled because of the substantial investment in healthcare technology, the widespread use of digital health solutions, and the well-developed healthcare infrastructure. In addition, the Asia Pacific region’s market is anticipated to experience expansion in the global market for digital therapeutics & medical devices for migraine due to the region’s rising healthcare spending and emphasis on research and innovation on non-pharmacological therapies for migraines. In addition, the Asia Pacific region is likely to experience industrial expansion because of the rising cost of healthcare, the incidence of migraine problems, and the growing interest in digital health solutions. This trend is further accelerated by the development of new technologies and the growth of healthcare infrastructure, which drives the market growth in this area.
Recent Developments:
- In January 2024, Neurolief is delighted to announce that Sawai Group Holdings Co., Ltd. made a strategic equity investment. An exclusive agreement was previously inked for the development and marketing of Neurolief’sRelivion, a groundbreaking non-invasive, at-home wearable electroceutical therapy for depression and migraines, in Japan. This investment further strengthens the strategic collaboration between Neurolief and the Japanese pharmaceutical corporation.
- In February 2024, Theranica, a leader in prescribed digital therapeutics, has announced that its Nerivio Remote Electrical Neuromodulation wearable, designed for the treatment and prevention of migraines, will be covered by a commercial insurance policy offered by Highmark Inc.
Digital Therapeutics & Medical Devices for Migraine Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 8.6% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Age Group, And Mode Of Action |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Relivion MG, gammaCore, WeatherX, Aculief, Theragun, Allay Lamp, Allodynic Therapeutics, LLC, Amgen Inc., Bayer AG, Cefaly Technology, Cirrus Healthcare Products, electroCore, Inc, Eli Lilly and Company, eNeura Inc., GlaxoSmithKline plc., Neurolief Ltd., Neuros Medical, Inc., Novartis AG, Pfizer Inc., Salvia BioElectronics B.V., and Theranica Bio-Electronics Ltd., and other market players. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
